These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 2143575)

  • 21. Meningococcal vaccines: Current state and future outlook.
    Leca M; Bornet C; Montana M; Curti C; Vanelle P
    Pathol Biol (Paris); 2015 Jun; 63(3):144-51. PubMed ID: 25986879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
    Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ
    Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the antimeningococcal immunoglobin activity against five strains of Neisseria meningitidis group B from Latin America using mice as model.
    Perez-Ramirez PJ; Infante Bourzac JF; Sifontes Rodriguez S; Caro Azoy E; Balboa Gonzalez J; Sierra Gonzalez G; Campa Huergo C; Capo de Paz V
    Arch Med Res; 1997; 28(4):591-5. PubMed ID: 9428590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
    Cohen R; Levy C
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunization with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci.
    Jolley KA; Appleby L; Wright JC; Christodoulides M; Heckels JE
    Infect Immun; 2001 Jun; 69(6):3809-16. PubMed ID: 11349046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neisseria meningitidis serogroup Y: incidence and description of clinical illness.
    Risko JA; Hodges GR
    Am J Med Sci; 1974 Jun; 267(6):345-52. PubMed ID: 4210436
    [No Abstract]   [Full Text] [Related]  

  • 27. [Serological evaluation of an antimeningococcal mass vaccination campaign in Niger].
    Rey JL; Soubiran G; Fayet MT; Triau R
    Bull Soc Pathol Exot Filiales; 1989; 82(2):248-54. PubMed ID: 2501041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Experience in obtaining group meningococcal antiserums (Sanitary-epidemiological station, Leninsk, Kzyl-Orlinsk district)].
    Polianin VA
    Lab Delo; 1975; (4):251-2. PubMed ID: 57303
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effectiveness of seroconversion of the Neisseria meningitidis serogroup C vaccine, duration of antibody levels in the Autonomic Community of Extremadura].
    Ramos Aceitero JM
    Rev Esp Salud Publica; 1998; 72(5):411-4. PubMed ID: 9951333
    [No Abstract]   [Full Text] [Related]  

  • 30. Complement factor 7 gene mutations in relation to meningococcal infection and clinical recurrence of meningococcal disease.
    Kuijpers TW; Nguyen M; Hopman CT; Nieuwenhuys E; Dewald G; Lankester AC; Roos A; van der Ende A; Fijen C; de Boer M
    Mol Immunol; 2010 Jan; 47(4):671-7. PubMed ID: 19931914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Practice patterns of infectious disease physicians for management of meningococcal disease.
    Terranella A; Beekmann SE; Polgreen PM; Cohn A; Wu HM; Clark TA
    Pediatr Infect Dis J; 2012 Nov; 31(11):e208-12. PubMed ID: 22705919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meningococci.
    Sippel JE
    Crit Rev Microbiol; 1981; 8(3):267-302. PubMed ID: 6781818
    [No Abstract]   [Full Text] [Related]  

  • 33. Management of meningococcal infections.
    Klein NJ; Heyderman RS; Levin M
    Br J Hosp Med; 1993 Jun 16-Jul 13; 50(1):42-9. PubMed ID: 8364705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges for development of meningococcal vaccines in infants and children.
    Deasy A; Read RC
    Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hospital costs, length of stay and mortality associated with childhood, adolescent and young adult meningococcal disease in the US.
    Davis KL; Bell TJ; Miller JM; Misurski DA; Bapat B
    Appl Health Econ Health Policy; 2011 May; 9(3):197-207. PubMed ID: 21506625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Tests of anti-meningococcal vaccination with A and C group polysaccharide vaccines].
    Galli MG; Fara GM; Saletti M; Porro M; Ribero ML
    Ann Sclavo; 1981; 23(3):356-66. PubMed ID: 6803687
    [No Abstract]   [Full Text] [Related]  

  • 38. T-cell-stimulating protein A elicits immune responses during meningococcal carriage and human disease.
    Robinson K; Wooldridge KG; Wells DB; Hasan A; Todd I; Robins A; James R; Ala'Aldeen DA
    Infect Immun; 2005 Aug; 73(8):4684-93. PubMed ID: 16040981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Group-specific A-antibodies in persons living in the foci of meningococcal infection].
    Zotova AB; Denisenko LI
    Zdravookhr Kirg; 1977; 0(6):35-9. PubMed ID: 24953
    [No Abstract]   [Full Text] [Related]  

  • 40. [Preventive meningococcal immunology].
    Vanderkerkove M; Triau R; Causse G
    Prog Immunobiol Stand; 1971; 5():478-84. PubMed ID: 4633974
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.